Sanofi Management Discusses Q2 2012 Results - Earnings Call Transcript

Sanofi (SNY)

Q2 2012 Earnings Call

July 26, 2012 8:30 am ET


Sébastien Martel

Christopher A. Viehbacher - Chief Executive Officer, Director and Member of Strategy Committee

Hanspeter Spek - President of Global Operations

Olivier Charmeil - Senior Vice President of Sanofi Pasteur - Vaccines Division

Jerome Contamine - Chief Financial Officer and Executive Vice President


Richard Vosser - JP Morgan Chase & Co, Research Division

Michael Leuchten - Barclays Capital, Research Division

Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Philippe Lanone - Natixis Bleichroeder LLC, Research Division

Graham Parry - BofA Merrill Lynch, Research Division

Jo Walton - Crédit Suisse AG, Research Division

Mark Clark - Deutsche Bank AG, Research Division

Peter Verdult - Morgan Stanley, Research Division

Vincent Meunier - Exane BNP Paribas, Research Division



Welcome to the Sanofi 2012 Second Quarter Results Conference Call. I now hand over to Mr. Sébastien Martel and to Mr. Christoph Viehbacher. Sir, please go ahead. .

Sébastien Martel

Thank you. Hi, everyone, and welcome to our second quarter conference call. As always I must advise you that the information presented today in the call contains forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially. So I'd like to please ask you refer to our Form 20-F on file with the SEC and also our Document de Référence for a description of these risk factors.

So with me today on the call are Chris Viehbacher, our CEO; Hanspeter Spek, our President of Global Operations; Olivier Charmeil, Senior VP for Vaccines; and Jerome Contamine, our CFO.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe